



A UNIQUE PARTNERING OPPORTUNITY

DNDi is looking for a Korean CDMO/partner with which we can jointly apply for project funding from the RIGHT Fund in September 2021. The Korean CDMO/partner will play a major role in improving the COGS of a novel DNDi compound that will enable the realization of low production costs, driving affordable pricing and sustainable supply of the resulting medicine bringing equitable access for patients in need.

The collaboration is envisaged in two steps:

1. API process optimization to demonstrate the feasibility of improving cost efficiency (e.g., utilization of continuous manufacturing)
2. If feasibility is demonstrated, continuation to full API development and commercialization activities.

ABOUT DNDi

Created in 2003, the Drugs for Neglected Diseases *initiative* (DNDi) is an international, not-for-profit research and development organization developing new treatments for neglected patients. Acting in the public interest, DNDi bridges existing R&D gaps in essential drugs for various diseases by initiating and coordinating drug R&D projects in collaboration with the international research community, the public sector, the pharmaceutical industry, and other relevant partners. DNDi's primary focus has been the development of drugs for the most neglected diseases, such as human African trypanosomiasis, visceral leishmaniasis (kala-azar), and Chagas disease, while considering engagement in R&D projects for other neglected patients (e.g. malaria, paediatric HIV, filarial infections, COVID patients in Africa).

Partnering with DNDi on behalf of neglected patients can be an optimal strategy for pharma companies and CRO/CDMO organizations to fulfil corporate social responsibility objectives, engage in the fields of global health and neglected disease R&D, and motivate employees interested in delivering medical innovations to people in need. See Annex 1.

DNDi as a foundation does not have its own funds. Since 2003, close to 60% of DNDi support has come from public institutions, slightly over 40% of the support has come from private sources.

[DNDi | Best science for the most neglected](#)

ABOUT THE RIGHT FUND

The RIGHT Fund, established in July of 2018, is the first Public-Private Partnership (PPP) funding agency in Korea dedicated to supporting global health R&D. The three-way partnership is between the Government of Korea, Korean life science companies, and international funders. The RIGHT Fund provides a platform for the government and Korean life science industry to increase their contributions to global health and will serve as a vehicle for investment in R&D projects aimed at delivering tangible products to address disease burden in developing countries.

[RIGHT Fund - 라이트펀드](#)

[Global Access Policy - Right Fund](#)

TIMELINES

Process steps	Responsible party	Timelines
Launch RFI	DNDi	25 June 2021
Send back the completed Excel questionnaire	Company	10 July 2021
Discussions under CDA with companies that provide satisfactory responses; budget preparation	DNDi; Company	mid-late July 2021
Partner selection	DNDi	early Aug 2021
Grant preparation	DNDi and Company	August-Sept 2021

CONTACT INFORMATION

Please kindly send any questions to both contacts below.

We request that you email the completed RFI Excel questionnaire to both contacts below.


Contact persons	Title	Contact information
Christophine Marty Moreau	Senior Procurement Manager	Phone: +41 22 906 92 61 Email: cmarty@dndi.org
Douglas Cary	R&D Liaison	Email: dcary@dndi.org

ANNEX 1

WIN –WIN PROPOSITION

1

Why should companies collaborate with DNDi?



¹ http://image-src.bcg.com/Images/BCG-Total-Societal-Impact-Oct-2017_tcm30-210654.pdf